Metalloproteinase inhibition protects against reductions in circulating adrenomedullin during lead-induced acute hypertension
Contribuinte(s) |
Universidade Estadual Paulista (UNESP) |
---|---|
Data(s) |
21/10/2015
21/10/2015
01/06/2015
|
Resumo |
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Processo FAPESP: 2013/21.305-1 Intoxication with lead (Pb) results in increased blood pressure by mechanisms involving matrix metalloproteinases (MMPs). Recent findings have revealed that MMP type two (MMP-2) seems to cleave vasoactive peptides. This study examined whether MMP-2 and MMP-9 levels/activities increase after acute intoxication with low lead concentrations and whether these changes were associated with increases in blood pressure and circulating endothelin-1 or with reductions in circulating adrenomedullin and calcitonin gene-related peptide (CGRP). Here, we expand previous findings and examine whether doxycycline (a MMPs inhibitor) affects these alterations. Wistar rats received intraperitoneally (i.p.) 1st dose 8g/100g of lead (or sodium) acetate, a subsequent dose of 0.1g/100g to cover daily loss and treatment with doxycycline (30mg/kg/day) or water by gavage for 7days. Similar whole-blood lead levels (9g/dL) were found in lead-exposed rats treated with either doxycycline or water. Lead-induced increases in systolic blood pressure (from 143 +/- 2 to 167 +/- 3mmHg) and gelatin zymography of plasma samples showed that lead increased MMP-9 (but not MMP-2) levels. Both lead-induced increased MMP-9 activity and hypertension were blunted by doxycycline. Doxycycline also prevented lead-induced reductions in circulating adrenomedullin. No significant changes in plasma levels of endothelin-1 or CGRP were found. Lead-induced decreases in nitric oxide markers and antioxidant status were not prevented by doxycycline. In conclusion, acute lead exposure increases blood pressure and MMP-9 activity, which were blunted by doxycycline. These findings suggest that MMP-9 may contribute with lead-induced hypertension by cleaving the vasodilatory peptide adrenomedullin, thereby inhibiting adrenomedullin-dependent lowering of blood pressure. |
Formato |
508-515 |
Identificador |
http://onlinelibrary.wiley.com/doi/10.1111/bcpt.12337/abstract Basic & Clinical Pharmacology & Toxicology. Hoboken: Wiley-blackwell, v. 116, n. 6, p. 508-515, 2015. 1742-7835 http://hdl.handle.net/11449/128574 http://dx.doi.org/10.1111/bcpt.12337 WOS:000354246100010 |
Idioma(s) |
eng |
Publicador |
Wiley-Blackwell |
Relação |
Basic & Clinical Pharmacology & Toxicology |
Direitos |
closedAccess |
Tipo |
info:eu-repo/semantics/article |